# Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction - DOSE Finding Study

> **NCT04270760** · PHASE2 · COMPLETED · sponsor: **Amgen** · enrollment: 281 (actual)

## Conditions studied

- Cardiovascular Disease

## Interventions

- **DRUG:** Olpasiran
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04270760
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-28
- **Primary completion:** 2021-12-27
- **Final completion:** 2022-11-08
- **Target enrollment:** 281 (ACTUAL)
- **Last updated:** 2026-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04270760

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04270760, "Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction - DOSE Finding Study". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT04270760. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*